Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 297-302

  Pastrone, Ilaria ^a   Viale, Maurizio ^a   Cafaggi, Sergio ^b   Mariggiò, Maria A ^c   Parodi, Arianna ^a   Esposito, Mauro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Anticancer drugs; DPR; P388 cells; Synergism

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN DERIVATIVE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PROCAINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; LEUKEMIA CELL LINE; LEUKEMIA P 388; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032449532     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006228027066     Document Type: Article

References (17)

1. Cafaggi S, Esposito M, Parodi B, Vannozzi MO, Viale M, Pellecchia C, Fulco RA, Merlo F, Zicca A, Cadoni A, Bignardi G: Synthesis and antitumor activity of a new cis-diammineplatinum(II) complex containing procaine hydrochloride. Anticancer Res 12: 2285-2292, 1992
2. Viale M, Vannozzi MO, Merlo F, Cafaggi S, Parodi B, Esposito M: Cisplatin combined with the new cisplatin-procaine complex DPR: in vitro and in vivo studies. Eur J Cancer 13: 2327-2333, 1996
3. Viale M, Cafaggi S, Parodi B, Esposito M: Cytotoxicity and cellular accumulation of a new cis-diammineplatinum(II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 35: 371-376, 1995
4. Zhang JG, Esposito M, Cafaggi S, Lindup WE: Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices. Hum Exp Toxicol 15: 59-63, 1996
5. Mandys V, Viale M, Vrana J, Cafaggi S, Esposito M: Neurotoxic effect of the cisplatin-procaine complex DPR studied in organotypic cultures of chick embryonic dorsal root ganglia. Anti-Cancer Drugs 9: 659-663, 1998
6. Viale M, Melioli G, Pasquetti W, Meta M, Cafaggi S, Esposito M: Modifications of cell cycle induced by DPR, a new platinum-triamine complex containing procaine. Int J Oncol 4: 1047-1051, 1994
7. Hussain RF, Nouri AME, Oliver RTD: A new approach for measurement of cytotoxicity using colorimetric assay. J Immunol Methods 160: 89-96, 1993
8. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3: 1-103, 1972
9. Berembaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1989
10. Berembaum MC: Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335, 1981
11. Scanlon K, Newman EM, Lu Y, Priest DG: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8935, 1986
12. Perez RP, Perez KM, Handel LM, Hamilton TC: In vitro interactions between platinum analogs in human ovarian-carcinoma cell lines. Cancer Chemother Pharmacol 29: 430-434, 1992
13. Jekunen AP, Christen RD, Shalinsky DR, Howell SB: Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69: 299-306, 1994
14. Lidor YJ, Shpall EJ, Peters WP, Bast RC, Jr: Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49: 704-710, 1991
15. Sorenson CM, Eastman A: Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48: 4484-4488, 1988
16. 2 phase and cell death induced by cisplatin. JNC1 82: 749-755, 1990
17. Peyrot B, Briand C, Momburg R, Sari JC: In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II). Biochem Pharmacol 35: 371-375, 1986